AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02195180
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01399905
Drug: carbidopa
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg of carbidopa per day versus 450 mg of carbidopa per day
Trial: NCT02577315
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
Trial: NCT02577315
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
Trial: NCT02577315
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
Trial: NCT02577315
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
Trial: NCT01596517
Drug: Peginterferon alfa-2a plus ribavirin for HCV genotype 1
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight \<75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
Trial: NCT01596517
Drug: Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
Trial: NCT01072734
Drug: Vaccine
RxNorm normalized name: VACCINES
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine
Trial: NCT01549171
Drug: Iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: supplement in culture medium during culture in the lab. The concentration is 1 uM.
Trial: NCT00702871
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
Trial: NCT00702871
Drug: Sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
Trial: NCT02199171
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via HIPEC
Trial: NCT00253851
Drug: unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
Trial: NCT01554345
Drug: vitamin E +Selenium
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
Trial: NCT01379989
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5
Trial: NCT01379989
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
Trial: NCT02556918
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
Trial: NCT03161626
Drug: Coagadex
RxNorm normalized name: Coagadex
DrugBank: Coagulation factor X human (DB13148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-driven blood coagulation factor X concentration
Trial: NCT02556918
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients that required continuous insulin infusion (CII) at a rate \>1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between \>180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG \>241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG \<100 mg/dl: stop basal
Trial: NCT02556918
Drug: Supplemental insulin (Insulin lispro)
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG greater than 400 mg/dL; 7-9 units of insulin lispro
Trial: NCT02556918
Drug: Supplemental insulin (Insulin aspart)
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG greater than 400 mg/dL; 7-9 units of insulin aspart
Trial: NCT00132925
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00470041
Drug: administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation
RxNorm normalized name: zidovudine and lamivudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00093743
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00093743
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT00093743
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT01905371
Drug: Dextroamphetamine
RxNorm normalized name: Dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01537120
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01346826
Drug: Accelerated 1 hour-infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7.
Trial: NCT01346826
Drug: Accelerated 30 minutes-infusion
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5.
Trial: NCT01904253
Drug: TAS-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Trial: NCT01904253
Drug: Amrubicin (Japan)
RxNorm normalized name: Valrubicin
DrugBank: Amrubicin (DB06263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive treatment administered according to the country-specific approved prescribing information
Trial: NCT01904253
Drug: Topotecan (Japan/Europe)
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive treatment administered according to the country-specific approved prescribing information
Trial: NCT00489489
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Film-coated tablet~Oral administration
Trial: NCT00489489
Drug: Placebo (for Teriflunomide)
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Film-coated tablet~Oral administration
Trial: NCT00489489
Drug: Interferon-β
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Trial: NCT04108546
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with lidocaine 2%, 1.5 ml, and Dexamethasone 8 mg
Trial: NCT03968744
Drug: Safinamide
RxNorm normalized name: Safinamide
DrugBank: Safinamide (DB06654)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Safinamide taken per Os for 12 weeks
Trial: NCT00755716
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg per day for one week, 50 mg per day for one week, 100 mg per day for one week, 200 mg per day for 5 weeks, then one week taper
Trial: NCT00755716
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
Trial: NCT00437086
Drug: PS-341
RxNorm normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg/m2 by IV; 4 out of 5 weeks
Trial: NCT00640146
Drug: Methylnaltrexone bromide
RxNorm normalized name: Methylnaltrexone Bromide
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
Trial: NCT00796744
Drug: NorLeu3-A(1-7) in a gel formulation
RxNorm normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
Trial: NCT00717925
Drug: Inotuzumab Ozogamicin (CMC-544)
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
Trial: NCT03422328
Drug: macitentan
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: macitentan 10 mg, film-coated tablet, oral use
Trial: NCT03145181
Drug: Teclistamab (IV)
RxNorm normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of Teclistamab.
Trial: NCT02464306
Drug: fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
Trial: NCT03145181
Drug: Teclistamab(SC)
RxNorm normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC injection of Teclistamab.
Trial: NCT02660047
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
Trial: NCT02660047
Drug: Liraglutide - Placebo
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
Trial: NCT04083950
Drug: Aspirin (Positive Control)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
Trial: NCT04127695
Drug: ABBV-0805
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-0805 administered by IV infusion.
Trial: NCT00304278
Drug: Erlotinib (Tarceva)
RxNorm normalized name: erlotinib Oral Tablet [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg daily X 7 weeks
Trial: NCT00304278
Drug: Intra-arterial Cisplatin (PLAT)
RxNorm normalized name: methotrexate
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 dose (150 mg/sq) per week X 4 weeks
Trial: NCT03310372
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
Trial: NCT02615041
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
Trial: NCT02615041
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem.
Trial: NCT02615041
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem.
Trial: NCT02375243
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine continous infusion 0.5 mcg/kg/h
Trial: NCT02932280
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
Trial: NCT00609804
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
Trial: NCT00609804
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg once daily by mouth
Trial: NCT02088541
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor oral tablet.
Trial: NCT02088541
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02088541
Drug: Ara-C
RxNorm normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ara-C Subcutaneous Injection.
Trial: NCT04005807
Drug: BPN-14967
RxNorm normalized name: BPN
DrugBank: Brompheniramine (DB00835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BPN-14967 oral capsules
Trial: NCT03941756
Drug: Indocyanine Green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02793557
Drug: FOL-005
RxNorm normalized name: Niva-Fol
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal injection of 50 μl solution
Trial: NCT02344602
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet, 80mg, OD, 8 weeks
Trial: NCT03751761
Drug: durvalumab, tremelimumab, paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
Trial: NCT03763409
Drug: Losartan Potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active drug
Trial: NCT02143713
Drug: Elagolix
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix tablets administered orally
Trial: NCT02720705
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral dexmedetomidine
Trial: NCT02471209
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: general anesthesia with 2% followed by 3% sevoflurane